Fviii has 1 known drug interaction based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Concizumab. Patients taking Fviii should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 1
- Major
- 1
Major (1)
- Fviii + Concizumab— High and/or frequent doses increase risk of thromboembolism. Lowest-approved dose recommended for mild to moderate bleed…